NCT03847428 2026-03-06
EMERALD-2
AstraZeneca
Phase 3 Active not recruiting
Clinical Trials
16 trialsNCT04039607 2026-02-19
CheckMate 9DW
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT03186898 2026-02-13
Radiation Therapy With Protons or Photons in Treating Patients With Liver Cancer
NRG Oncology
Phase 3 Active not recruiting
NCT04712643 2026-01-30
A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT05198609 2026-01-21
Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized Trial
Sun Yat-sen University
Phase 3 Active not recruiting
NCT03778957 2026-01-16
EMERALD-1
AstraZeneca
Phase 3 Active not recruiting
NCT03298451 2026-01-14
HIMALAYA
AstraZeneca
Phase 3 Active not recruiting
NCT03654053 2026-01-07
SACRED
VA Office of Research and Development
Phase 3 Active not recruiting
NCT05904886 2025-12-31
SKYSCRAPER-14
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT04639180 2025-12-30
A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Active not recruiting
NCT04246177 2025-12-17
LEAP-012
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT03755791 2025-12-11
COSMIC-312
Exelixis
Phase 3 Active not recruiting
NCT04194775 2025-12-11
A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma
CStone Pharmaceuticals
Phase 3 Active not recruiting
NCT05320692 2025-12-11
A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Active not recruiting
NCT03383458 2025-11-21
CheckMate 9DX
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT05301842 2025-01-15
EMERALD-3
AstraZeneca
Phase 3 Active not recruiting